Today is the Worst GLP1s+ Will Ever Be GLP1s+ More effective (5% to 22% weight loss and on their way to 25%+) More expansive disease management (diabetes, obesity, CVD, CKD, OSA, and studied for more) Less frequent (2x per day to 1x week and on their way to 1x/month to 1x/year?) Additional effective options in orals are on their way Insurance Coverage Medicare adding coverage for CVD (hopefully more diseases on the way as labels expand) Medicaid added 5 states in just 2023 Federal government added all employees and family members in 2023 Commercial employer coverage increased by 35% in 2023, with more employers considering it The Treat and Reduce Obesity Act (TROA) has been introduced in Congress to encourage Medicare coverage Costs Zepbound, a more effective drug, launched ~20-30% cheaper than Wegovy, with a savings card that put it at just over 1/3rd of the price at the time
Myth #4: The Medication Is Too New or Unsafe This medication has been extensively studied over the last decade and has a strong safety and efficacy track record
Doi:10.1155/2014/151479 Sikiric P, Hahm KB, Blagaic AB, et al
Brands like Ozempic (for diabetes) and Wegovy (for weight loss) together contributed an estimated $25.4 billion in global revenues in 2024, highlighting the immense commercial potential
ISRCTN Registry, ResearchGate 2 Glucose control & metabolic markers in type 2 diabetes / pre-diabetes 14 g/day for 852 weeks 2024 dose-response meta-analysis of 36 RCTs (n=3 214) found clinically meaningful reductions in fasting glucose (9 mg/dL), HbA1c (0.32 %) and HOMA-IR (0.43)
